Table 1 Associations between patient and tumor characteristics and TP53 status (IHC, RNA) in CBCS3
From: TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases
IHC average weighted percent Positivity ≥10% | NanoString TP53 gene expression signature | |||||||
|---|---|---|---|---|---|---|---|---|
Mutant (≥10%) | Wild type (<10%) | Mutant | Wild type | |||||
N (%a) | N (%a) | RFDb (95% CI) | p-value | N (%a) | N (%a) | RFDb (95% CI) | p-value | |
Total | 312 (21.3) | 979 (78.7) | 491 (40.9) | 522 (59.1) | ||||
Age | ||||||||
≤50 years | 145 (29.8) | 461 (28.0) | 1.8 (−1.7, 5.3) | 0.31 | 263 (34.4) | 247 (28.6) | 5.8 (2.4, 9.2) | <0.01 |
>50 years | 167 (70.2) | 518 (72.0) | Ref. | 228 (65.6) | 275 (71.4) | Ref. | ||
Grade | ||||||||
Low-Intermediate | 65 (28.6) | 620 (75.0) | Ref. | 102 (26.2) | 392 (82.2) | Ref. | ||
High | 232 (71.4) | 295 (25.0) | 46.4 (42.8, 49.9) | <0.01 | 381 (73.8) | 108 (17.8) | 56.0 (52.9, 59.1) | <0.01 |
Missing | 15 | 64 | 8 | 22 | ||||
Stage | ||||||||
I, II | 259 (84.3) | 848 (88.9) | Ref. | 392 (80.3) | 449 (87.2) | Ref. | ||
III, IV | 51 (15.7) | 118 (11.1) | 4.5 (1.8, 7.2) | <0.01 | 98 (19.7) | 68 (12.8) | 6.9 (4.2, 9.6) | <0.01 |
Missing | 2 | 13 | 1 | 5 | ||||
Node Status | ||||||||
positive | 108 (33.8) | 363 (32.7) | 1.1 (-2.5, 4.7) | 0.54 | 222 (44.3) | 204 (36.6) | 7.7 (4.1, 11.2) | <0.01 |
negative | 202 (66.2) | 614 (67.3) | Ref. | 267 (55.7) | 317 (63.4) | Ref. | ||
missing | 2 | 2 | 2 | 1 | ||||
Tumor Size | ||||||||
≤2 cm | 159 (57.1) | 570 (64.9) | Ref. | 199 (44.4) | 306 (64.3) | Ref. | ||
>2 cm | 149 (42.9) | 382 (35.1) | 7.8 (0.4, 11.5) | <0.01 | 288 (55.6) | 208 (35.7) | 19.9 (16.3, 23.5) | <0.01 |
missing | 4 | 27 | 4 | 8 | ||||
ER Status | ||||||||
positive | 118 (46.6) | 800 (86.7) | Ref. | <0.01 | 207 (44.6) | 487 (96.5) | Ref. | |
negative | 190 (53.4) | 153 (13.3) | 40.1 (36.5, 43.7) | 280 (55.4) | 27 (3.5) | 51.9 (49.0, 54.8) | <0.01 | |
missing | 4 | 26 | 4 | 8 | ||||
PR Status | ||||||||
positive | 83 (33.9) | 634 (69.1) | Ref. | <0.01 | 140 (29.8) | 408 (82.5) | Ref. | |
negative | 223 (66.1) | 316 (30.9) | 35.2 (31.6, 38.9) | 343 (70.2) | 103 (17.5) | 52.7 (49.5, 55.8) | <0.01 | |
missing | 6 | 29 | 8 | 11 | ||||
HER2 Status | ||||||||
negative | 251 (83.9) | 821 (88.4) | Ref. | 379 (79.8) | 469 (94.0) | Ref. | ||
positive | 54 (16.1) | 117 (11.6) | 4.5 (1.8, 7.3) | <0.01 | 101 (20.2) | 38 (6.0) | 14.2 (11.7, 16.7) | <0.01 |
missing | 7 | 41 | 11 | 15 | ||||
HR+/Her2− | ||||||||
ER+ or PR+/HER2− | 90 (45.7) | 707 (89.1) | Ref. | 152 (43.2) | 448 (97.1) | Ref. | ||
ER-/PR-/HER2− | 158 (54.3) | 112 (10.9) | 43.3 (39.4, 47.2) | <0.01 | 224 (56.8) | 21 (2.9) | 53.8 (50.6, 57.1) | <0.01 |
missing | 64 | 160 | 115 | 53 | ||||
PAM50 Subtype | ||||||||
Luminal A/B | 59 (30.1) | 441 (74.5) | Ref. | 111 (22.5) | 476 (91.8) | Ref. | ||
Basal-like, HER2, Normal-like | 161 (69.9) | 182 (25.5) | 44.4 (40.2, 48.7) | <0.01 | 380 (77.5) | 46 (8.2) | 69.3 (66.6, 71.9) | <0.01 |
missing | 92 | 356 | ||||||
